TY - JOUR T1 - Morphine Interaction with Aspirin: a Double-blind, Cross-over Trial in Healthy Volunteers JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther DO - 10.1124/jpet.117.247213 SP - jpet.117.247213 AU - Johann Bartko AU - Christian Schoergenhofer AU - Michael Schwameis AU - Patricia Wadowski AU - Jacek Kubica AU - Bernd Jilma AU - Eva-Luise Hobl Y1 - 2018/01/01 UR - http://jpet.aspetjournals.org/content/early/2018/03/14/jpet.117.247213.abstract N2 - Aspirin is a cornerstone in the anti-platelet therapy of acute coronary syndromes. Co-administration of morphine may potentially influence the intestinal absorption, pharmacokinetics and pharmacodynamics as seen with P2Y12-inhibitors. In this trial, healthy volunteers were randomized to receive morphine (5 mg, iv bolus injection) at one of 7 different time points before, after or with aspirin (162 mg, po) in a double-blind, placebo controlled fashion. After a 14-day washout, subjects received placebo instead of morphine. Pharmacokinetics were determined by liquid-chromatography and aspirin effects were measured by platelet function tests (whole blood platelet aggregation: Multiplate, platelet plug formation: PFA-100). Morphine increased the total acetylsalicylic acid exposure by 20% compared to placebo when given simultaneously with aspirin, whereas Cmax and tmax were not altered. Morphine had no significant effect on aspirin-induced platelet inhibition. In contrast to co-administration with P2Y12-inhibitors, morphine appears to have negligible interaction with aspirin. ER -